In pancreatic cancer, approximately 30% of tumors carry a de novo acquired, pancreatic-cancer-specific super-enhancer with marked H3K27 acetylation located near the 3′ region of MYC [90,91]. This evidence concerns the gene MYC and pancreatic neoplasm.